NeoStem Achieves New Milestone as Company Joins Russell 3000 Index
"Joining the Russell indices represents an important milestone inNeoStem's history. As part of the Russell indices, we see the opportunity toincrease the Company's visibility within the investment community and furtherdiversify our shareholder base," said Robin Smith, NeoStem's Chairman and CEO."Our selection to join the indexes reflects the increase in the Company'smarket capitalization over the past year and the positive momentum as weadvance our adult stem cell therapies in China and the acquisition of aprofitable and growing majority-owned pharmaceutical subsidiary, Suzhou Erye."
Annual reconstitution of Russell's U.S. indexes captures the 3,000 largestU.S. stocks as of the end of May, ranking them by total market capitalization.Membership in the Russell 3000, which remains in place for one year, meansautomatic inclusion in the large-cap Russell 1000 Index or small-cap Russell2000 Index as well as the appropriate growth and value style indexes. Russelldetermines membership for its equity indexes primarily by objective,market-capitalization rankings and style attributes.
The Russell 3000 also serves as the U.S. component to the Russell GlobalIndex, launched in 2007.
Russell indexes are widely used by investment managers and institutionalinvestors for index funds and as benchmarks for both passive and activeinvestment strategies. An industry-leading $3.9 trillion in assets currentlyare benchmarked to them. These investment tools originated from Russell'smulti-manager investment business in the early 1980s when the company saw theneed for a more objective, market-driven set of benchmarks in order toevaluate outside investment managers.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapiesand building of a network of adult stem cell collection centers in the U.S.and China that are focused on enabling people to donate and store their own(autologous) stem cells for their personal use in times of future medical need.The Company is also the licensee of various stem cell technologies, includinga worldwide exclusive license to VSEL(TM) Technology which uses very smallembryonic-like stem cells, shown to have several physical characteristics thatare generally found in embryonic stem cells, and is pursuing the licensing ofother technologies for therapeutic use. NeoStem's majority-controlled Chinesepharmaceutical operation, Suzhou Erye, manufactures and distributes genericantibiotics in China. For more information, please visit:http://www.neostem.com .
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Forward-lookingstatements reflect management's current expectations, as of the date of thispress release, and involve certain risks and uncertainties. Forward lookingstatements include the likelihood of inclusion in any Russell index, aboutwhich no assurances can be given. The Company's actual results could differmaterially from those anticipated in these forward- looking statements as aresult of various factors. Factors that could cause future results tomaterially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company'sAnnual Report on Form 10-K filed with the Securities and Exchange Commissionon March 31, 2010, as well as other periodic filings made with the Securitiesand Exchange Commission. The Company's further development is highly dependenton future medical and research developments and market acceptance, which isoutside its control.For more information, please contact: NeoStem, Inc. Robin Smith, CEO Phone: +1-212-584-4174 Email: email@example.com Web: http://www.neostem.com CCG Investor Relations, Inc. Crocker Coulson, President Phone: +1-646-213-1915 Email: firstname.lastname@example.org Web: http://www.ccgirasia.com
SOURCE NeoStem, Inc.
You May Also Like